A Review on Formulation and Evaluation of Nanoniosomal Topical gel of Paclitaxel for skin cancer

Author:

Abdin Nasrina1,Pratap Sahu Bhanu1,Sofiur Rahman Sheikh1

Affiliation:

1. Department of Pharmaceutics, Girijananda Chowdury Institute of Pharmaceutical Science, Hatkhowapara, Azara, Guwahati, Assam, India. Pin code: 781017.

Abstract

Cancer is the second leading cause of death in the world and one of the major public health problems. Despite the great advances in cancer therapy, the incidence and mortality rates of cancer remain high. Therefore, the goal for more efficient and less toxic cancer treatment strategies is still at the forefront of current research. Despite these efforts, cancer drug research remains a remarkably challenging field, and therapeutic innovations have not yet achieved expected clinical results. However, the physiopathology of the disease is now better understood, and the discovery of novel molecular targets has refreshed the expectations of developing improved treatments. Paclitaxel (PCT) is a chemotherapeutic agent used as a first-line treatment for a wide range of cancers, such as lung, ovarian, breast, prostate, head, and neck cancers, and AIDS-related Kaposi sarcoma. Currently, the marketed forms of Paclitaxel are intravenous formulations. Oral administration of Paclitaxel is unfortunately hampered due to its low bioavailability. This is explained by its low aqueous solubility, low permeability, high affinity for cytochrome P450 and P-glycoprotein. As another approach, drug carrier systems are extensively studied to enhance oral Paclitaxel bioavailability and reduce side effects. The niosomes provides several important advantages over conventional drug therapy. Structurally, niosomes are similar to liposomes, in that they are also made up of a bilayer. However, the bilayer in the case of niosomes is made up of non-ionic surface-active agents rather than phospholipids as seen in case of liposomes. Niosome nanoparticles are among these drug delivery systems, which have numerous applications in drug delivery and targeting. Niosomes are frequently used for loading drugs serving different purposes (e.g., anticancer, antiviral, and antibacterial agents). The aim of this review is to evaluate the extent of nanotherapeutics used in anti-cancer activity.

Publisher

A and V Publications

Subject

Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Reference58 articles.

1. Roger Walker, Clive Edwards. Cancer disease. In Roger Walker, The Textbook of Clinical pharmacy and Therapeutics, Third Edition. New Delhi, Jaypee Brothers Medical Publishers [P] Ltd. 2003; 265-353.

2. Peppa LB, Blanchette JO. Nanoparticle and targeted system for cancer therapy. Adv Drug Deliv Rev. 2004; 56: 1649-1659. https://doi.org/10.1016/j.addr.2004.02.014

3. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochem Biophys Acta. 1995; 1233: 134-144. https://doi.org/10.1016/0005-2736(94)00235-h

4. Katragadda U, Fan W, Wang Y, Teng Q, Tan C. Combined delivery of Paclitaxel and Tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis. 2013; 8(3): e58619. https://doi.org/10.1371/journal.pone.0058619

5. Jang SH, Wientjes MG, Au JLS. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther. 2001; 296: 1035-1042

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Preparation and Evaluation of Niosomal Transdermal Patch of Clozapine;Asian Journal of Research in Pharmaceutical Sciences;2023-03-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3